The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
| ||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| MERUS N V | COM | N5749R100 | 19,360 | 1,600,000 | SH | SOLE | 1,2,3 | 1,600,000 | 0 | 0 | |
| OBSEVA SA | COM | H5861P103 | 3,783 | 1,570,000 | SH | SOLE | 1,2,3 | 1,570,000 | 0 | 0 | |
| PHATHOM PHARMACEUTICALS INC | COM | 71722W107 | 53,392 | 2,067,861 | SH | SOLE | 1,2,3 | 2,067,861 | 0 | 0 | |